Intrinsiqq
Sanofi SA logo

Sanofi SA Financials

SAN.XPAR

⊜ Compare

All currency values in € millions unless otherwise noted

Scroll

Income Statement
TTM
DEC 2025
DEC 2024
DEC 2023
DEC 2022
DEC 2021
Revenues
Revenue€48,919€46,716€44,286€46,444€45,389€39,175
Cost of Revenue€13,323€13,049€13,205€14,236€13,695€12,255
Gross Profit€35,596€33,667€31,081€32,208€31,694€26,920
Total Operating Expenses€25,528€24,070€21,619€21,816€19,813€17,773
Operating Income€10,068€9,597€9,462€10,392€11,881€9,147
Non-Operating
Net Interest Expense-€730-€626-€749-€659-€461-€389
Income Tax Expense€1,203€1,043€1,204€1,602€2,006€1,558
Net Income
Net Income€4,011€7,851€5,618€5,436€8,484€6,279
Per Share Data
Revenue Per Share€40.88€38.28€35.39€37.10€36.26€31.28
EPS (Basic)€3.35€6.40€4.59€4.31€5.37€4.97
EPS (Diluted)€3.35€6.40€4.59€4.31€5.37€4.97
Shares Outstanding1.20B1.22B1.25B1.25B1.25B1.25B
Dividends Per Share€4.12€4.12€3.92€3.76€3.56€3.33

Sanofi SA (SAN.XPAR) financials: revenue, profit and margins

Sanofi SA (SAN.XPAR) generated about €48.9 billion in revenue and €4.0 billion in net income (a 8.2% net margin) over the trailing twelve months, growing at roughly 4.5% a year. Figures are from company filings; this is analysis, not investment advice.

Frequently asked

What is Sanofi SA's (SAN.XPAR) revenue?+

Sanofi SA generated about €48.9 billion in revenue over the trailing twelve months. Revenue has grown at roughly 4.5% a year over the past five years. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.

Is Sanofi SA profitable?+

Yes, Sanofi SA reported about €4.0 billion in net income over the trailing twelve months, a net profit margin of roughly 8.2%. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

What are Sanofi SA's profit margins?+

Sanofi SA runs a gross margin of about 72.8%, an operating margin of about 20.6%, a net margin of about 8.2%. Margins show how much of each sales dollar a company keeps at each stage. Stable or rising margins usually signal pricing power and cost discipline; falling margins are worth investigating. See the multi-year trend on this tab.

How fast is Sanofi SA growing?+

Sanofi SA's revenue has compounded at roughly 4.5% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside SAN.XPAR's margins and free cash flow. This is analysis from company filings, not investment advice.

How the market compares: How many US companies are profitable

Peers

Drug Manufacturers - General · Pick stocks to compare with SAN.XPAR

CompareIntrinsic value
RNO.XPARRenault SA
€28.63+5.10%27
FR.XPARValeo
€10.98+0.50%54
RMS.XPARHermès International
€1,372.50+4.57%62
KER.XPARKering S.A.
€191.70+6.36%26
CDI.XPARChristian Dior SE
€453.20+4.14%50
MC.XPARLVMH Moët Hennessy
€416.25+3.67%48
FNAC.XPARFnac Darty SA
€34.90+0.00%44
BUR.XPARBurelle SA
€324.00-0.92%60

Held by ETFs

SAN.XPAR is in 168 US ETFs. The largest of them, with SAN.XPAR's weight in each:

Spot a number that looks wrong?

Download this analysis as a PDF (Pro)

Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing SAN.XPAR

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.